IL3 Stock Overview Manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Integra LifeSciences Holdings Corporation Competitors Price History & Performance
Summary of share price highs, lows and changes for Integra LifeSciences Holdings Historical stock prices Current Share Price US$25.00 52 Week High US$41.60 52 Week Low US$15.30 Beta 1.18 1 Month Change 11.61% 3 Month Change 0.81% 1 Year Change -34.21% 3 Year Change -56.52% 5 Year Change -53.27% Change since IPO 254.86%
Recent News & Updates
Integra LifeSciences Holdings Corporation to Report Q4, 2024 Results on Feb 25, 2025 Feb 04
Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs) Jan 15 Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Updates Earnings Guidance for the Full Year of 2024
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.24 profit in 3Q 2023) Nov 04
Investor sentiment deteriorates as stock falls 21% Aug 05
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.052 profit in 2Q 2023) Jul 30 See more updates
Integra LifeSciences Holdings Corporation to Report Q4, 2024 Results on Feb 25, 2025 Feb 04
Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs) Jan 15 Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Updates Earnings Guidance for the Full Year of 2024
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.24 profit in 3Q 2023) Nov 04
Investor sentiment deteriorates as stock falls 21% Aug 05
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.052 profit in 2Q 2023) Jul 30
Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Third Quarter and Updates Earnings Guidance for the Full Year of 2024 Jul 30
Integra LifeSciences Holdings Corporation to Report Q2, 2024 Results on Jul 29, 2024 Jul 16
Integra LifeSciences Holdings Corporation(NasdaqGS:IART) dropped from Russell 1000 Dynamic Index Jul 03
Independent Presiding Director recently bought €917k worth of stock May 23
Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2024 May 08
New minor risk - Share price stability May 07
First quarter 2024 earnings released: US$0.042 loss per share (vs US$0.30 profit in 1Q 2023) May 06
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million. Apr 03 Integra LifeSciences Holdings Corporation to Report Q1, 2024 Results on Apr 25, 2024
Integra LifeSciences Holdings Corporation, Annual General Meeting, May 09, 2024 Mar 27
Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases Mar 12
Investor sentiment deteriorates as stock falls 19% Mar 06 Integra LifeSciences Holdings Corporation Announces Board Changes
Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the First Quarter and for the Full Year 2024 Feb 29
Full year 2023 earnings released: EPS: US$0.84 (vs US$2.18 in FY 2022) Feb 29
Integra LifeSciences Holdings Corporation to Report Q4, 2023 Results on Feb 28, 2024 Feb 08
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million. Dec 14 Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.
Third quarter 2023 earnings released: EPS: US$0.24 (vs US$0.60 in 3Q 2022) Oct 26
Levi & Korsinsky Notifies Integra Lifesciences Holdings Corporation Investors of a Class Action Lawsuit and Upcoming Deadline Oct 20
Integra LifeSciences Holdings Corporation to Report Q3, 2023 Results on Oct 25, 2023 Oct 05
Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation Sep 14
Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation Sep 13
New minor risk - Earnings quality Jul 30 Integra LifeSciences Holdings Corporation (NasdaqGS:IART) announces an Equity Buyback for $225 million worth of its shares.
Second quarter 2023 earnings released: EPS: US$0.052 (vs US$0.54 in 2Q 2022) Jul 27
Integra LifeSciences Holdings Corporation to Report Q2, 2023 Results on Jul 27, 2023 Jul 04 Integra LifeSciences Holding Corporation Announces Complete Enrollment in DuraSorb Monofilament Mesh U.S. IDE Study Jun 29
Integra Lifesciences Holdings Corporation Appoints Lea Daniels Knight as Executive Vice President, Effective June 28, 2023
President recently bought €279k worth of stock Jun 04
Now 35% undervalued after recent price drop May 24
Now 20% undervalued after recent price drop May 03
First quarter 2023 earnings released: EPS: US$0.29 (vs US$0.39 in 1Q 2022) Apr 27
Insider recently sold €95k worth of stock Mar 09
Insider recently sold €203k worth of stock Mar 01
Full year 2022 earnings released: EPS: US$2.16 (vs US$2.00 in FY 2021) Feb 23
Now 20% undervalued Feb 18 Integra LifeSciences Holdings Corporation Announces Executive Changes
Now 21% undervalued Jan 26 Integra LifeSciences Holdings Corporation Provides Revenue Guidance for Fourth Quarter 2022 and Full-Year 2022
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) completed the acquisition of Surgical Innovation Associates, Inc. Dec 07
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire Surgical Innovation Associates, Inc. for $140 million. Dec 02
Third quarter 2022 earnings released: EPS: US$0.60 (vs US$0.51 in 3Q 2021) Oct 27
Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year Oct 27
Integra LifeSciences Holdings Corporation to Report Q3, 2022 Results on Oct 26, 2022 Oct 09
Integra LifeSciences Holdings Corporation Appoints Harvinder Singh as Executive Vice President and President of Integra’s International Business Oct 07
Integra LifeSciences Holdings Corporation Announces Resignation of Glenn Coleman as Chief Operating Officer, Effective October 3, 2022 Aug 30
Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO Aug 17
Independent Director recently sold €439k worth of stock Aug 09
An unknown buyer entered into a definitive agreement to acquire Non-core Traditional Wound Care Business of Integra LifeSciences Holdings Corporation (NasdaqGS:IART) for $28.8 million. Jul 29
Second quarter 2022 earnings released: EPS: US$0.54 (vs US$0.41 in 2Q 2021) Jul 28 Integra LifeSciences Holdings Corporation Revises Financial Guidance for the Third Quarter and Full Year 2022
Integra LifeSciences Holdings Corporation Appoints Renee Lo to its Board of Directors Jul 20
Integra LifeSciences Holdings Corporation to Report Q2, 2022 Results on Jul 27, 2022 Jul 02
First quarter 2022 earnings released: EPS: US$0.39 (vs US$0.54 in 1Q 2021) Apr 28
Integra LifeSciences Holdings Corporation, Annual General Meeting, May 13, 2022 Apr 09
Integra LifeSciences Holdings Corporation to Report Q1, 2022 Results on Apr 27, 2022 Apr 02
Insider recently sold €75k worth of stock Mar 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the First Quarter and Full Year 2022 Feb 24
Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2021 Jan 12
Insider recently sold €214k worth of stock Nov 09
Third quarter 2021 earnings released: EPS US$0.51 (vs US$0.38 in 3Q 2020) Nov 03
Insider recently sold €242k worth of stock Aug 11
Second quarter 2021 earnings released: EPS US$0.41 (vs US$0.004 loss in 2Q 2020) Jul 29
Integra LifeSciences Announces Positive Clinical Outcomes for Primatrix® Dermal Repair Scaffold for the Management of Diabetic Foot Ulcers Jul 20
Independent Director recently sold €69k worth of stock Jun 08
Integra Lifesciences Holdings Corporation Reaffirms Earnings Guidance for Second Quarter and Full Year 2021 May 21
First quarter 2021 earnings released: EPS US$0.53 (vs US$0.11 in 1Q 2020) Apr 30
Integra Lifesciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2021 Apr 29
Independent Director has left the company Mar 01
Insider recently sold €1.4m worth of stock Feb 28
Full year 2020 earnings released: EPS US$1.57 (vs US$0.59 in FY 2019) Feb 20
Revenue beats expectations Feb 20
Integra LifeSciences Holdings Corporation Announces Board Changes, Effective February 26, 2021 Feb 13
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) completed the acquisition of ACell, Inc. Jan 22
Integra LifeSciences Holdings Corporation to Report Q4, 2020 Results on Feb 18, 2021 Jan 15
New 90-day high: €55.00 Jan 14 Shareholder Returns IL3 DE Medical Equipment DE Market 7D 0.8% -0.2% -0.2% 1Y -34.2% -4.7% 13.7%
See full shareholder returns
Return vs Market: IL3 underperformed the German Market which returned 12.9% over the past year.
Price Volatility Is IL3's price volatile compared to industry and market? IL3 volatility IL3 Average Weekly Movement 5.9% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: IL3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: IL3's weekly volatility (6%) has been stable over the past year.
About the Company Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Show more Integra LifeSciences Holdings Corporation Fundamentals Summary How do Integra LifeSciences Holdings's earnings and revenue compare to its market cap? IL3 fundamental statistics Market cap €1.93b Earnings (TTM ) -€6.29m Revenue (TTM ) €1.50b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IL3 income statement (TTM ) Revenue US$1.56b Cost of Revenue US$632.40m Gross Profit US$932.52m Other Expenses US$939.06m Earnings -US$6.54m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
Earnings per share (EPS) -0.085 Gross Margin 59.59% Net Profit Margin -0.42% Debt/Equity Ratio 118.9%
How did IL3 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/05 06:24 End of Day Share Price 2025/02/05 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Integra LifeSciences Holdings Corporation is covered by 30 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Toung Argus Research Company Matthew Taylor Barclays Charley Jones Barrington Research Associates, Inc.
Show 27 more analysts 
